These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 2817084)
1. Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Jordon D; Jagirdar J; Kaneko M Am J Pathol; 1989 Nov; 135(5):931-7. PubMed ID: 2817084 [TBL] [Abstract][Full Text] [Related]
2. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877 [TBL] [Abstract][Full Text] [Related]
3. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
4. Malignant mesotheliomas. Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44-3A6 and 624A12. Lee I; Radosevich JA; Chejfec G; Ma YX; Warren WH; Rosen ST; Gould VE Am J Pathol; 1986 Jun; 123(3):497-507. PubMed ID: 3717302 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of membranous staining of mesothelioma. King JA; Tucker JA Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721 [TBL] [Abstract][Full Text] [Related]
7. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review]. Galateau-Salle F Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582 [TBL] [Abstract][Full Text] [Related]
8. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. Comin CE; Novelli L; Boddi V; Paglierani M; Dini S Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372 [TBL] [Abstract][Full Text] [Related]
9. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects]. Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062 [TBL] [Abstract][Full Text] [Related]
10. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Shield PW; Koivurinne K Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095 [TBL] [Abstract][Full Text] [Related]
11. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Corson JM; Pinkus GS Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295 [TBL] [Abstract][Full Text] [Related]
12. Differential diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic antigen. Ernst CS; Atkinson B; Chianese D; Peters J; Perry M; Herlyn M; Koprowski H Appl Pathol; 1986; 4(3):115-24. PubMed ID: 2885017 [TBL] [Abstract][Full Text] [Related]
13. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. O'Hara CJ; Corson JM; Pinkus GS; Stahel RA Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835 [TBL] [Abstract][Full Text] [Related]
14. E-cadherin, E-selectin and vascular cell adhesion molecule: immunohistochemical markers for differentiation between mesothelioma and metastatic pulmonary adenocarcinoma? Müller AM; Weichert A; Müller KM Virchows Arch; 2002 Jul; 441(1):41-6. PubMed ID: 12111199 [TBL] [Abstract][Full Text] [Related]
15. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen. Sheibani K; Battifora H; Burke JS Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942 [TBL] [Abstract][Full Text] [Related]
16. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Ylagan LR; Zhai J Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Lane Z; Hansel DE; Epstein JI Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358 [TBL] [Abstract][Full Text] [Related]
18. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Deniz H; Kibar Y; Güldür ME; Bakir K Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998 [TBL] [Abstract][Full Text] [Related]
19. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Afify AM; Stern R; Michael CW Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337 [TBL] [Abstract][Full Text] [Related]
20. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Frisman DM; McCarthy WF; Schleiff P; Buckner SB; Nocito JD; O'Leary TJ Mod Pathol; 1993 Mar; 6(2):179-84. PubMed ID: 8483888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]